Related Experiment Video
Updated: Jan 12, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.4K
Dupilumab efficacy by disease severity in pediatric type 2 asthma
Daniel J Jackson1, Monika Gappa2, Leonard B Bacharier3
1University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Summary
Long-term dupilumab treatment effectively reduced asthma exacerbations and improved lung function in children with moderate-to-severe type 2 asthma. These benefits were observed regardless of initial disease severity, indicating broad efficacy for this asthma biologic.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Clinical Pharmacology
Background:
- Dupilumab has shown efficacy in pediatric asthma patients.
- This study is a post hoc analysis of the VOYAGE and EXCURSION trials.
- The analysis focuses on long-term dupilumab efficacy based on asthma severity at baseline.
Purpose of the Study:
- To assess the long-term efficacy of dupilumab in children with moderate-to-severe type 2 asthma.
- To evaluate efficacy based on asthma severity (moderate vs. severe) at the start of the parent study.
Main Methods:
- Children aged 6-11 years with moderate-to-severe type 2 asthma were included.
- Participants received dupilumab every 2 weeks for an additional 52 weeks.
- Outcomes measured included severe exacerbation rates, lung function (FEV1, FEV1 z-score), and asthma control (ACQ-7-IA).
Main Results:
- Dupilumab significantly reduced annualized severe exacerbation rates in both moderate and severe asthma subgroups compared to placebo.
- Sustained reductions in exacerbations were observed during the extension study.
- Improvements in pre-bronchodilator percent predicted FEV1, FEV1 z-scores, and ACQ-7-IA scores were noted in both subgroups, with greater numerical improvements in severe asthma.
Conclusions:
- Long-term dupilumab treatment improves lung function and asthma control in children with type 2 asthma.
- Efficacy was observed irrespective of baseline disease severity.
- Numerically greater improvements were seen in children with severe asthma.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:24Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K